St Jude's LightLab files new lawsuit against Volcano's Axsun
This article was originally published in Clinica
St Jude Medical subsidiary LightLab is persisting in its legal battle with rival Axsun Technologies, a subsidiary of Volcano, by filing a new lawsuit which claims that Axsun used LightLab's trade secret information to develop its optical coherence tomography technology. This is the second lawsuit that LightLab has filed in relation to this matter: earlier this year, the Superior Court of Massachusetts rejected LightLab's similar claims after two years of litigation (www.clinica.co.uk, 24 February 2011). Volcano incurred $4.9m in legal expenses, as well as its own litigation costs of $2.8m. The latest lawsuit was filed in a Delaware court. San Diego, California-based Volcano denies the "unfounded" allegations. "Volcano firmly believes that this latest lawsuit has no merit, and looks forward to the opportunity of proving so in court".
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.